Glenview State Bank Trust DEPT. Has $1.86 Million Stake in Celgene Co. (NASDAQ:CELG)

Glenview State Bank Trust DEPT. decreased its position in shares of Celgene Co. (NASDAQ:CELG) by 2.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,080 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. Glenview State Bank Trust DEPT.’s holdings in Celgene were worth $1,856,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CELG. Archford Capital Strategies LLC raised its position in shares of Celgene by 277.8% during the first quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares during the last quarter. Investors Research Corp acquired a new position in shares of Celgene during the first quarter valued at about $28,000. Weaver Consulting Group acquired a new position in shares of Celgene during the first quarter valued at about $29,000. Alera Investment Advisors LLC raised its position in shares of Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 167 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Celgene during the first quarter valued at about $31,000. 74.77% of the stock is owned by hedge funds and other institutional investors.

NASDAQ CELG opened at $93.57 on Wednesday. The company has a market capitalization of $66.32 billion, a PE ratio of 12.30, a P/E/G ratio of 0.44 and a beta of 1.46. The company has a 50-day simple moving average of $93.14. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $98.97. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44.

Celgene (NASDAQ:CELG) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.17. The business had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.22 billion. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.16 earnings per share. As a group, equities analysts predict that Celgene Co. will post 9.96 EPS for the current year.

A number of brokerages have recently commented on CELG. ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Saturday. Mizuho reaffirmed a “buy” rating and set a $103.00 price objective on shares of Celgene in a research report on Wednesday, July 3rd. Cowen reaffirmed a “hold” rating and set a $102.00 price objective on shares of Celgene in a research report on Tuesday, July 30th. Finally, Barclays cut shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have given a buy rating to the stock. Celgene has a consensus rating of “Hold” and an average target price of $94.81.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Trading on Margin

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.